Approved aphthous ulcer treatment (Aphthasol) being repurposed as metabolic compound. Inhibits TBK1 and IKKε kinases, reversing metabolic effects of obesity-induced inflammation. Studied for weight loss, insulin sensitivity, and NASH.
Amlexanox is a compound that has been used as a prescription treatment for canker sores (aphthous ulcers) in the United States and has been approved in Japan for asthma and allergies for many years. More recently, researchers have been studying whether it might have applications in metabolic conditions including type 2 diabetes and obesity, based on its effect on specific inflammatory signaling proteins.
Oral Ulcer Treatment
Amlexanox was FDA-approved as a topical paste for aphthous ulcers (canker sores). Clinical trials showed it reduced the size and duration of ulcers and reduced associated pain compared to placebo. This represents its most established application.
Metabolic and Obesity Research
Researchers discovered that amlexanox inhibits two related kinases — IKK-epsilon and TBK1 — that are involved in inflammation-driven metabolic dysfunction. A small human trial in obese patients with type 2 diabetes or metabolic syndrome found that some participants had improvements in blood sugar, liver fat, and body weight.
Anti-Inflammatory Mechanisms
Because IKK-epsilon and TBK1 are part of pathways that link chronic inflammation to insulin resistance, amlexanox has been studied in the context of metabolic inflammation. Animal studies showed improvements in insulin sensitivity and energy expenditure through this mechanism.
Established efficacy for topical treatment of aphthous ulcers in clinical trials.
A small human trial in metabolic patients found improvements in some metabolic markers in a subset of participants.
Animal studies show significant improvements in insulin sensitivity and energy expenditure through IKK-epsilon/TBK1 inhibition.
The metabolic application remains at an early research stage with limited human data.
The metabolic research on amlexanox is at an early stage. The human metabolic trial was small and the results were not uniform across participants — only a subset showed meaningful response. Larger trials have not been completed. Its established use is as a topical treatment for canker sores, and the systemic metabolic effects observed in small studies would need to be confirmed in larger controlled trials before any conclusions could be drawn.
Amlexanox blocks two enzymes — IKK-epsilon and TBK1 — that are activated during chronic low-grade inflammation. In people with obesity or type 2 diabetes, these enzymes are often overactive, and their activity appears to blunt the body's response to insulin and reduce the amount of energy burned at rest. By blocking these enzymes, amlexanox may help restore normal insulin signaling and increase energy expenditure. Think of it as dampening an inflammatory signal that was interfering with the body's normal metabolic regulation.
Amlexanox has a long history of use as a topical treatment for canker sores and is generally well-tolerated at that application. For systemic metabolic use, the safety data are limited to small trials. Common side effects in the metabolic trial included mild nausea and diarrhea. It is not currently approved for metabolic conditions. Its use for anything beyond aphthous ulcer treatment should be considered off-label and investigational.
Preliminary
Most evidence comes from preclinical studies and case reports. Human data is limited and more research is needed.
Published Research Ranges
25–100mg twice daily oral in metabolic research studies
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Amlexanox Reverses Obesity and Insulin Resistance in Mice via IKKe and TBK1
A clinical evaluation of amlexanox oral adhesive pellicles in the treatment of recurrent aphthous stomatitis and comparison with amlexanox oral tablets: a randomized, placebo controlled, blinded, multicenter clinical trial
Effectiveness of 0.1% triamcinolone acetonide compared with those of other therapies for minor recurrent aphthous stomatitis: a systematic review and meta-analysis of randomized controlled trials
Single application of topical doxycycline in management of recurrent aphthous stomatitis: a systematic review and meta-analysis of the available evidence
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.